Re-Importation: A Looming Antitrust Concern for Biotechs?
Executive SummaryWith federal legislation to allow drug reimportation mired in the US Senate following passage of a bill in the House of Representatives last year, US biotechs must wrestle with an immediate question: how to prevent their ex-US partners from becoming sources of low-cost imports of their products?
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.